Neuphoria Therapeutics reported net income of -$0.51M for the quarter ended Mar 2026. This income statement covers 15 quarters of results from Jun 2020 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Jun2021 | Jun2022 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||
| Revenue | 0.66M | 15.00M | -0.01M | ||||||||||||
| Operating items | |||||||||||||||
| Research & DevelopmentR&D | 3.09M | 2.03M | 1.20M | 3.10M | 1.90M | 1.74M | 1.62M | 3.75M | 3.79M | 0.70M | |||||
| Selling, General & AdministrativeSG&A | 2.38M | 2.52M | 1.20M | 2.38M | 1.67M | 2.63M | 1.41M | 2.07M | 1.87M | 2.13M | 1.69M | ||||
| Restructuring CostsRestructuring | 1.24M | 0.04M | |||||||||||||
| Other Operating ExpensesOther Opex | -0.52M | ||||||||||||||
| Operating ExpensesOpex | 5.47M | 4.55M | 2.39M | 5.48M | 3.57M | 4.37M | 3.02M | 5.82M | 5.65M | 4.06M | 1.21M | ||||
| Operating IncomeOp. Inc | -5.47M | -4.55M | -2.39M | -5.48M | -3.57M | -3.70M | 11.98M | -5.84M | -5.65M | -4.06M | -1.21M | ||||
| EBIT | -5.47M | -4.55M | -2.39M | -5.48M | -3.57M | -3.70M | 11.98M | -5.84M | -5.65M | -4.06M | -1.21M | ||||
| Non-operating items | |||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.09M | 0.05M | 0.05M | 0.03M | 0.04M | 0.03M | 0.01M | 0.09M | 0.14M | 0.17M | 0.19M | ||||
| Other Non Operating IncomeOther Non Op Inc. | -0.00M | -0.36M | 0.22M | -0.31M | -0.28M | 0.63M | 0.17M | -0.94M | -0.06M | -0.14M | -0.29M | ||||
| Non Operating IncomeNon Op. Inc. | -0.04M | -0.04M | -0.37M | 2.76M | 2.63M | 1.77M | -0.80M | -3.32M | -4.29M | 5.89M | 0.67M | ||||
| Net income details | |||||||||||||||
| EBT | -5.51M | -4.59M | -2.76M | -2.72M | -0.94M | -1.93M | 11.18M | -15.42M | -9.94M | 1.83M | -0.54M | ||||
| Tax ProvisionsTaxes | -0.03M | -0.03M | 0.02M | -3.84M | -0.13M | 0.01M | -0.08M | -0.27M | -0.03M | -0.03M | -0.03M | ||||
| Profit After TaxPAT | -5.47M | -4.55M | -3.34M | -2.52M | -0.80M | -1.94M | 11.30M | -8.91M | -9.91M | 1.86M | -0.51M | ||||
| Income from Continuing OperationsIncome (Continuing) | -5.47M | -4.55M | -2.78M | 1.12M | -0.80M | -1.94M | 11.26M | -15.16M | -9.91M | 1.86M | -0.51M | ||||
| Consolidated Net IncomeConsol Net Inc. | -5.47M | -4.55M | -2.78M | 1.12M | -0.80M | -1.94M | 11.26M | -15.16M | -9.91M | 1.86M | -0.51M | ||||
| Income towards Parent CompanyParent Net Inc | -5.47M | -4.55M | -2.78M | 1.12M | -0.80M | -1.94M | 11.26M | -15.16M | -9.91M | 1.86M | -0.51M | ||||
| Net Income towards Common StockholdersNet Income | -5.47M | -4.55M | -2.78M | 1.12M | -0.80M | -1.94M | 11.26M | -15.16M | -9.91M | 1.86M | -0.51M | ||||
| Additional items | |||||||||||||||
| EPS (Basic) | -0.04 | -0.04 | -0.02 | 0.01 | -0.01 | -0.02 | 0.09 | -0.12 | -0.08 | 0.01 | 0.00 | ||||
| EPS (Diluted) | -0.04 | -0.04 | -0.02 | 0.01 | -0.01 | -0.02 | 0.09 | -0.12 | -0.08 | 0.01 | 0.00 | ||||
| Shares Outstanding | 45.40M | 64.99M | 112.77M | 122.39M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 45.40M | 64.99M | 112.77M | 122.39M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M | 124.66M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 52.18M | 64.99M | 112.77M | 123.89M | 124.66M | ||||||||||
| EBITDA | -5.47M | -4.55M | -2.39M | -5.48M | -3.57M | -3.70M | 11.98M | -5.84M | -5.65M | -4.06M | -1.21M | ||||
| Tax Rate | 0.63% | 0.76% | -0.59% | 141.18% | 14.11% | -0.60% | -0.73% | 1.73% | 0.35% | -1.90% | 6.44% |